Vijaya Diagnostic Centre Ltd. · NSE:VIJAYA
Vijaya Diagnostic Centre — Q3 FY25 Earnings Presentation
48 slides from Vijaya Diagnostic Centre's earnings presentation, Feb 12, 2025
Slide 1: Cover letter to stock exchanges
February 12, 2025 To, To, The Listing Department The Corporate Relations Department National Stock Exchange Of India Limited, BSE Limited, Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, 25th floor, Dalal Street, Bandra (East), Mumbai - 400 051 Mumbai - 400 001 NSE Symbol: VIJAYA BS
Slide 2: Q3 & 9M FY25 Earnings Presentation
Q3 & 9M FY25 Earnings Presentation February 12, 2025 Q2 & H1 FY25 Earnings Presentation, November 07, 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for
Slide 4: Disclaimer
Disclaimer Disclaimer Note 1: Acquisition (PH Diagnostic Centre Private Limited, Pune) : PH has become a whole owned subsidiary effective from 21st December 2023. Consequently, its financials have been consolidated from 21st December 2023 in the last financial year FY 2023-24. Hence, the consolidate
Slide 5: Q3 & 9M FY25 Performance Snapshot
Q3 & 9M FY25 Performance Snapshot Strategic Expansion
Slide 6: Q3 FY25 Performance Snapshot
Q3 FY25 Performance Snapshot Financial Performance Key Metrics INR 1,690 Mn INR 1,580 Mn 1.05 Mn 3.68 Mn Revenue from Operations Revenue excluding PH Footfall Tests INR 671 Mn | 39.7% INR 352 Mn | 20.8% 149 93% EBITDA | EBITDA Margin % PAT | PAT Margin % Centres B2C Revenue % YOY Growth % Geographic
Slide 7: 9M FY25 Performance Snapshot
9M FY25 Performance Snapshot Financial Performance Key Metrics INR 5,081 Mn INR 4,736 Mn 3.14 Mn 11.00 Mn Revenue from Operations Revenue excluding PH Footfall Tests INR 2,044 Mn | 40.2% INR 1,084 Mn | 21.3% 149 93% EBITDA | EBITDA Margin % PAT | PAT Margin % Centres B2C Revenue % YOY Growth % (1) G
Slide 8: Management Commentary
Management Commentary “ I’m pleased to announce another strong quarter, marked by a remarkable year-on-year revenue growth of 27.3%, with a solid 20.2% growth achieved organically. This strong performance was primarily driven by volume across both Pathology and Radiology segments. I am happy to shar
Slide 9: Key Financial Highlights – Q3 & 9M FY25
Key Financial Highlights – Q3 & 9M FY25 Revenue from Operations (INR Mn) EBITDA & EBITDA Margin % PAT & PAT Margin % 39.4% 41.5% 39.7% 40.2% 40.2% 19.5% 22.9% 20.8% 21.7% 21.3% 5,081 2,044 3,926 1,578 Key Financials 1,829 1,690 1,084 1,327 854 760 671 523 419 259 352 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24
Slide 10: Key Operational Highlights
Key Operational Highlights Tests Performed (# in Mn) Footfalls (# in Mn) Tests / Footfalls (# in Mn) 11.00 3.52 3.50 3.14 3.49 8.53 2.57 3.32 3.29 3.95 3.68 1.13 2.88 0.88 1.05 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Rev
Slide 11: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars Q3 FY25 Q3 FY24 Y-o-Y Q2 FY25 Q-o-Q 9M FY25 9M FY24 Y-o-Y Revenue from operations 1,689.8 1,326.9 27.3% 1,829.5 -7.6% 5,081.5 3,926.0 29.4% Cost of materials consumed 208.5 159.9 30.4% 229.9 -9.3% 626.0 466.2 34.3% Employee benefits expense 285.5 230.
Slide 12: Key Developments
Key Developments Strategic Expansion
Slide 13: Strengthening Leadership Team for the Next Leg of Growth
1 Strengthening Leadership Team for the Next Leg of Growth Sivaramaraju Vegesna Elevated from Head – Strategy & Investor Relations VP - Operations VP - Sales AGM – Strategy & GM - Strategy Investor Relations Praveen Velmury Vishal Gurram Dhiren Gala Total Experience: 3 Decades+ Total Experience: 12+
Slide 14: Inaugurated a state-of-the-art Hub in Nizamabad, Telangana
2 Inaugurated a state-of-the-art Hub in Nizamabad, Telangana Inaugurated State-of-the-Art Hub in Nizamabad in Nov, 2024 in line with our focus on expansion in key geographies within Tier II & Tier III cities Nizamabad 9,000+ sq.ft. Hub New Benchmark set with houses advanced “All Under One Roof equip
Slide 15: Inaugurated a Spoke in Bhuvanagiri, Telangana
3 Inaugurated a Spoke in Bhuvanagiri, Telangana Inaugurated a Spoke in Bhuvanagiri in Nov, 2024 in line with our strategy of deepening presence in our core markets Bhuvanagiri The spoke 1,500+ sq.ft. Spoke houses enhances our machinery for X-Ray, ECG Telangana market and all kinds of Blood Tests foo
Slide 16: Introduced PET-CT Machine in Tirupati Centre, AP
4 Introduced PET-CT Machine in Tirupati Centre, AP PET-CT machine has been successfully introduced at Tirupati Centre, AP in Nov, 2024 Tirupati City hosts established Strategic introduction medical centers, based on significant Oncology focused cancer infra investments hospitals & a growing by Govt
Slide 17: Received No-Objection Letter from Stock Exchanges
5 Received No-Objection Letter from Stock Exchanges Received No-objection letter from stock exchanges for the merger between Vijaya Diagnostics and Medinova Diagnostic Services in December, 2024 The NCLT process has commenced and is expected to conclude in 4-5 months 16
Slide 18: Strategic Expansion
Strategic Expansion Strategic Expansion
Slide 19: Expanding Strategically in Alignment with our Vision
Expanding Strategically in Alignment with our Vision Inorganic Expansion Strategy • Successfully acquired PH, Pune's largest B2C integrated diagnostic chain • This strategic acquisition seamlessly aligns with our commitment to providing top-notch East India Strategy healthcare services at affordable
Slide 20: Expansion Plans - Upcoming Hubs and Spokes Centres
Expansion Plans - Upcoming Hubs and Spokes Centres Tentative Timelines for Geography Count & Type Next 3 months Commencement Pune 2 Hubs Next 3 months 2 Spokes 6 2 Next 3 months Hubs Spokes 2 Hubs in next 3 months Next 5 Hubs 3 - 6 months West Bengal 3 Hubs in next 3-6 months 3 2 Bengaluru 2 Hubs Ne
Slide 21: Company Overview
Company Overview Strategic Expansion
Slide 22: Vijaya at a Glance
Vijaya at a Glance Vijaya Diagnostic Centre is the largest integrated diagnostic chain in South India with 149 state-of-the-art centres spread across 25 cities & towns Evolved from a regional player to a player with presence in multiple geographies … … While retaining its core values of providing Qu
Slide 23: Our Journey
Our Journey 1981 1993 1995 2007 20032012 2005 2016 ▪ Vijaya Diagnostic Centre ▪ Became 1st Independent diagnostic ▪ Recognized as one of the Best ▪ Received investment from incorporated in Hyderabad centre in South India to offer PET CT Imaging centres in Hyderabad Karakoram Limited & Kedaara from W
Slide 24: Integrated Diagnostics Player Offering One-Stop Solution
Integrated Diagnostics Player Offering One-Stop Solution Complete Range of Diagnostic Services under One Roof Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience 37% Pathology (1) 63% Radiology (1) 23 1. Reven
Slide 25: Dominant Position in Telangana & AP Markets with a Strong Brand Recall
Dominant Position in Telangana & AP Markets with a Strong Brand Recall … Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets Present in Key Geographies of AP & Telangana 72 (1) % Hyderabad Revenue Contribution Mancherial
Slide 26: Driving Geographical Diversification through Strategic Expansion
… and Driving Geographical Diversification through Strategic Expansion Gurgaon Hyderabad Pune RoAPT West Bengal Kalaburagi 78% 83% 72% 73% 18% 18% 17% 14% Geographical 6% 7% Revenue Mix 2% 4% 3% 3% 2% 0% Q3 FY25 Q2 FY25 FY24 FY23 Q3 FY25 Q2 FY25 FY24 FY23 Q3 FY25 Q2 FY25 FY24 FY23 Q3 FY25 Q2 FY25 FY
Slide 27: Boosting Accessibility with Best-in-class Online Services & Home Collections
Boosting Accessibility with Best-in-class Online Services & Home Collections Online Services Home Collections Enhancing Customer Experience through Seamless Online App, E-Commerce Website and Call Centre Bookings Elevating Customer Experience through Home Collections Access to reports online & histo
Slide 28: Robust Technical Capabilities with State-of-the-art IT Infrastructure
Robust Technical Capabilities with State-of-the-art IT Infrastructure 33 9 Advanced Software to Manage Clinical Data CT Machines PET CT / Gamma machines 33 300+ MRI Machines Fully Integrated Radiology Radiologists, Lab Doctors & Advance Laboratory Information Systems (RIS) and Physicians Information
Slide 29: Transitioned to AI Power Pack Radiology Software in Q3 FY25
Transitioned to AI Power Pack Radiology Software in Q3 FY25 Digitised Images Digitised Reports High Quality Reports Faster TAT ▪ Digitised Radiology images ▪ Radiology test reports can be ▪ Since the work list is ▪ Helps enhance customer can be shared with the accessed online by the centralised, it
Slide 30: Experienced Board of Directors
Experienced Board of Directors Ms. Suprita Reddy Dr. S. Surendranath Reddy Mr. Sunil Chandra Kondapally S Geeta Reddy Managing Director & Chief Founder & Exec. Chairman Executive Director Non-Executive Director Executive Officer ✔ 40+ years of experience ✔ 22+ years of experience ✔ 35+ years of expe
Slide 31: Stellar Management Team
Stellar Management Team Ms. Suprita Reddy Mr. Sunil Chandra Dr. S. Surendranath Reddy Mr. Narasimha Raju K.A Managing Director & Chief Kondapally Founder & Exec. Chairman Chief Financial Officer Executive Officer Executive Director ✔ 40+ years of experience ✔ 22+ years of experience ✔ 22+ years of e
Slide 32: Shareholding Pattern as at 31st December, 2024
Shareholding Pattern as at 31st December, 2024 Shareholding Pattern as at 31st December, 2024 Others 4.0% FIIs 17.5% Promoter & Promoter Group 53.9% DIIs 24.6% DIIs: Mutual Funds, AIFs and QIBs FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs Others: Retail, Bod
Slide 33: Doctors Connect Program in Q3 FY25
Doctors Connect Program in Q3 FY25 Vijaya Diagnostics organised a webinar on Ovarian-Adnexal Reporting & Data Vijaya Diagnostics organised a webinar on the role of CECT abdomen in system Ultrasonic (O-RADS US) management of pancreatic carcinoma Vijaya Diagnostics organised a webinar on Xray scannogr
Slide 34: Awards & Accolades
Awards & Accolades Fastest Growing Leaders 2023- Fastest Growing Brands 2023- Icon in Integrated Diagnostic Most Preferred Workplace for Most Trusted Brand of India 24 awarded at Asian business & 24 awarded at Asian business & Services by Times Health Women 2024 – 25 recognized 2024-25 awarded by So
Slide 35: Disclaimer
Disclaimer Note 2: Disclaimer "With effect from 01 January 2023, the Company has changed its method of depreciation on all Property, Plant and Equipment from Written Down Value (“WDV") method to Straight Line Method (“SLM"), based upon the technical assessment of expected pattern of consumption of t
Slide 36: Annexure
Annexure Strategic Expansion
Slide 37: State-of-the-art Infrastructure (1/3)
State-of-the-art Infrastructure (1/3) 36
Slide 38: State-of-the-art Infrastructure (2/3)
State-of-the-art Infrastructure (2/3) 37
Slide 39: State-of-the-art Infrastructure (3/3)
State-of-the-art Infrastructure (3/3) 38
Slide 40: Advanced Equipment in Place to Deliver High Quality Services (1/2)
Advanced Equipment in Place to Deliver High Quality Services (1/2) 39
Slide 41: Advanced Equipment in Place to Deliver High Quality Services (2/2)
Advanced Equipment in Place to Deliver High Quality Services (2/2) 40
Slide 42: Robust Operational Metrics
Robust Operational Metrics Diagnostic Centre (Nos) Footfalls (Mn) Tests Performed (Mn) 3.62 3.55 11.89 3.18 145 2.79 10.05 2.63 9.32 121 7.91 95 7.09 73 80 FY20 FY21 FY22 FY23 FY 24 FY20 FY21 FY22 FY23 FY 24 FY20 FY21 FY22 FY23 FY 24 Test per Footfall (Nos) Revenue per Test (INR) Revenue per Footfal
Slide 43: Consistent Financial Performance
Consistent Financial Performance Revenue EBIDTA PAT CAGR:12.8% CAGR:13.6% CAGR:17.4% 5,478 2,209 4,624 4,592 2,037 1,188 1,660 1,820 1,097 3,388 3,767 845 846 1,326 625 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 EBIDTA Margin (%) PAT Margin (%) 120 bps 320 bps 22.4% 2
Slide 44: Sustainable Cash Generation & Increasing Return Ratios
Sustainable Cash Generation & Increasing Return Ratios Cash & Cash Equivalents CFO (1) / EBIDTA (%) (INR Mn) 2,466 2,554 90% 2,277 1,729 1,822 83% 80% 78% 77% FY20 FY21 FY22 FY23 FY 24 FY20 FY21 FY22 FY23 FY 24 RoCE Pre-Cash (2) (%) RoE (%) 23% 23% 23% 43% 38% 18% 33% 16% 25% 23% FY20 FY21 FY22 FY23
Slide 45: Consolidated Profit & Loss Account
Consolidated Profit & Loss Account Particulars FY24 FY23 FY22 FY21 FY20 Revenue from operations 5,478 4,592 4,624 3,767 3,388 Cost of materials consumed 654 589 715 571 439 Employee benefits expense 902 785 707 574 624 Other expenses 1,712 1,398 1,165 962 999 EBITDA 2,209 1,820 2,037 1,660 1,326 EBI
Slide 46: Consolidated Balance Sheet
Consolidated Balance Sheet Assets Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Equity & Liabilities Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 NON-CURRENT ASSETS 7,714 5,777 4,436 3,022 2,959 EQUITY 6,599 5,466 4,695 3,592 2,741 Property, plant and equipment 3,785 2,940 1,966 1,358 1,398 Equity share capital 102 102
Slide 47: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Cash Flow from Operating Activities Profit before Tax 1,587 1,135 1,474 1,121 834 Adjustment for Non-Operating Items 599 683 572 534 492 Operating Profit before Working Capital Changes 2,186 1,818 2,046 1,655 1,326 Chang
Slide 48: Thank You
Thank You For further information please contact: Mr. Dhiren Gala AGM - Strategy & Investor Relations +91 90598 93206 dhiren.g@vijayadiagnostic.in ir@vijayadiagnostic.in www.vijayadiagnostic.com Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana
Vijaya Diagnostic Centre — Q3 FY25 Earnings Presentation on 6ix